Download MendeleyPeptidylarginine Deiminase (PAD) Inhibitor Optimization through Displacement of a Trapped Water Molecule.
Schnute, M.E., Chinigo, G.M., Futatsugi, K., Yamaguchi, M., Bagley, S.W., Banker, M.E., Chang, J.S., Chen, M.Z., Choi, W.Y., Corbett, M.S., Drozda, S.E., Ebner, D.C., Garcia-Irizarry, C., Hicklin, R., Hoy, S., Jiao, W., Kortum, S., Lee, K.L., Limburg, D.C., Lovering, F., Moreno, A., Mousseau, J.J., Pan, S., Parikh, M.D., Pelker, J.W., Ramsey, S., Reilly, U., Rescourio, G., Schmitt, D.C., Simpson, B., Skrzypek, G.J., Smaltz, D.J., Taylor, A.P., Torella, R., Trujillo, J.I., Vajdos, F.F., Wepy, J.A., Wright, S.W., Blakemore, D.C., Vincent, F., Clerin, V.M.(2025) ACS Med Chem Lett 16: 1662-1669
- PubMed: 40832545
- DOI: https://doi.org/10.1021/acsmedchemlett.5c00372
- Primary Citation of Related Structures:
9OVQ - PubMed Abstract:
Excess protein citrullination, a post-translational modification converting arginine to citrulline, has been associated with a range of autoimmune and neurological disorders, as well as cancers. Protein citrullination is mediated by the peptidylarginine deiminase enzyme family (PAD1-4), and inhibition of one or several PAD isozymes in combination may offer a therapeutic approach to targeting these diseases. Building upon the discovery of PAD-PF2, an allosteric inhibitor of PAD1-4, herein, we report on the optimization of potency and pharmacokinetic properties while minimizing hERG channel liabilities within this novel chemical series. Through structure-based ligand design, a structural water was successfully displaced, allowing expansion of the ligand binding site and access to a previously unexplored hydrophobic pocket resulting in a 10-fold improvement in potency. Compound 4f demonstrated potent inhibition of PAD-mediated citrullination in human and rat neutrophils, reduced hERG channel liabilities, and good oral bioavailability in preclinical animal species.
- Medicine Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States.
Organizational Affiliation:
